Avid is a clinical-stage product-focused molecular imaging company with significant expertise and IP in the field of molecular brain imaging. Avid has developed proprietary targeting agents to image amyloid plaques and is currently testing these compounds in clinical trials for the detection of Alzheimer's disease. Avid is now in Phase III studies with its lead amyloid imaging agent, AV-45. The Avid team has also developed novel agents targeted to the vesicular monoamine transporter (VMAT-2) to image pathology in dementia with Lewy bodies (DLB) and Parkinson's disease (PD) and has a research project in diabetes mellitus (DM). These agents have the potential to revolutionize early diagnosis and monitoring of disease.